ClinicalTrials.gg

Program

roxadustat

Also written as “Roxadustat”, “FG-4592” and “ASP1517”.

Its studies are mostly in Anemia · Renal Insufficiency, Chronic · Kidney Failure, Chronic · Myelodysplastic Syndromes · Renal Insufficiency, led by 3 companies.

Furthest: phase 4, since Jun 25, 201347 company-led studies, 2 open or runningNext primary completion: Oct 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharma221 open or runningphase 3since Jun 25, 2013Sep 15, 2009Oct 30, 2027phase 3 · NCT05970172
Kyntra Bio221 open or runningphase 4since Aug 8, 2019Sep 25, 2008Sep 2030phase 3 · NCT07722988
AstraZeneca30 open or runningphase 4since Dec 3, 2020Jun 24, 2014none ahead

Also a collaborator on its studies: parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 33 studies since Sep 25, 2008.

  1. Nov 13, 2016Phase 3 study in Renal Insufficiency, ChronicAstellas Pharma · NCT02964936 · 100 enrolled · Japan
  2. Dec 8, 2016Phase 3 study in Renal Insufficiency, ChronicAstellas Pharma · NCT02988973 · 334 enrolled · Japan
  3. Aug 22, 2017Phase 3 study in AnemiaKyntra Bio · NCT03263091 · 184 enrolled · United States, Australia, Belgium and more
  4. Oct 2, 2017Phase 3 study in AnemiaKyntra Bio · NCT03303066 · 43 enrolled · China
  5. May 21, 2019Phase 1 study in Healthy Adult SubjectsAstellas Pharma · NCT03960489 · 24 enrolled · Germany
  6. Aug 8, 2019Phase 4 study in AnemiaKyntra Bio · NCT04059913 · 318 enrolled · China
  7. Aug 30, 2019Phase 2 study in AnemiaKyntra Bio · NCT04076943 · 92 enrolled · United States
  8. May 27, 2020Phase 3 study in Anemia Associated With End Stage Renal Disease (ESRD)Kyntra Bio · NCT04410198 · 203 enrolled · United States
  9. Jul 21, 2020Phase 3 study in Anemia Associated With End Stage Renal DiseaseKyntra Bio · NCT04484857 · 283 enrolled · United States
  10. Nov 3, 2020Phase 3 study in AnemiaKyntra Bio · NCT04621331 · United States
  11. Dec 3, 2020Phase 4 study in Renal Insufficiency, ChronicAstraZeneca · NCT04655027 · 25 enrolled · China
  12. Mar 19, 2022Phase 3 study in Chemotherapy Induced AnemiaKyntra Bio · NCT05301517 · 159 enrolled · China
  13. Jul 25, 2023Phase 3 study in Renal Insufficiency, ChronicAstellas Pharma · NCT05970172 · 98 enrolled · Belgium, Croatia, Denmark and more
  14. Jul 20, 2026Phase 3 study in Myelodysplastic SyndromesKyntra Bio · NCT07722988 · 201 planned

Ahead

  1. Oct 30, 2027Primary completion: phase 3 study in Renal Insufficiency, ChronicAstellas Pharma · NCT05970172
  2. Sep 2030Primary completion: phase 3 study in Myelodysplastic SyndromesKyntra Bio · NCT07722988

TargetBeta

“Hypoxia-inducible factor prolyl hydroxylase inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
daprodustatruleGlaxoSmithKlinephase 333

Studies

All 47 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07722988Myelodysplastic Syndromes3Not yet recruitingKyntra BioSep 2030201
NCT05970172Renal Insufficiency, Chronic · Belgium, Croatia, Denmark and more3Active, not recruitingAstellas PharmaOct 30, 202798
NCT05301517Chemotherapy Induced Anemia · China3CompletedKyntra BioApr 3, 2023159
NCT04655027Renal Insufficiency, Chronic · China4CompletedAstraZenecaOct 12, 202125
NCT04621331Anemia · United States3WithdrawnKyntra BioMay 23, 20220
NCT04484857Anemia Associated With End Stage Renal Disease · United States3CompletedKyntra BioJul 9, 2021283
NCT04410198Anemia Associated With End Stage Renal Disease (ESRD) · United States3CompletedKyntra BioJun 30, 2021203
NCT04076943Anemia · United States2CompletedKyntra BioMar 26, 202192
NCT04059913Anemia · China4CompletedKyntra BioNov 19, 2021318
NCT03960489Healthy Adult Subjects · Germany1CompletedAstellas PharmaOct 14, 201924
NCT03303066Anemia · China3CompletedKyntra BioJan 11, 202343
NCT03263091Anemia · United States, Australia, Belgium and more3TerminatedKyntra BioMar 9, 2023184
NCT02988973Renal Insufficiency, Chronic · Japan3CompletedAstellas PharmaSep 13, 2019334
NCT02964936Renal Insufficiency, Chronic · Japan3CompletedAstellas PharmaAug 15, 2018100
NCT02965040Renal Insufficiency · Germany, United Kingdom1CompletedAstellas PharmaDec 4, 201734
NCT02952092Hemodialysis Chronic Kidney Disease Patients With Anemia · Japan3CompletedAstellas PharmaMar 13, 2018303
NCT02952040Healthy Subjects · Japan1CompletedAstellas PharmaDec 201618
NCT02805374Healthy Subjects · Japan1CompletedAstellas PharmaAug 201616
NCT02780726Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia · Japan3CompletedAstellas PharmaAug 2, 201756
NCT02780141ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia · Japan3CompletedAstellas PharmaDec 12, 201775
NCT02779764Hemodialysis Patients With Renal Anemia · Japan3CompletedAstellas PharmaMay 16, 2017164
NCT02693613Healthy Volunteers · Japan1CompletedAstellas PharmaApr 201634
NCT02652819Anemia · China3CompletedKyntra BioJan 24, 2017154
NCT02652806Anemia · China3CompletedKyntra BioJan 24, 2017305
NCT02278341Anemia · Belgium, Bulgaria, Croatia and more3CompletedAstellas PharmaJun 8, 2017838
NCT02273726Anemia · United States, Puerto Rico3CompletedKyntra BioSep 19, 2018741
NCT02174731Anemia · United States, Australia, Bulgaria and more3CompletedAstraZenecaSep 26, 20182,133
NCT02174627Anemia · United States, Argentina, Brazil and more3CompletedAstraZenecaOct 4, 20182,781
NCT02252731Pharmacokinetics of FG-4592 · Germany1CompletedAstellas PharmaNov 201322
NCT02161796PK for FG-4592 · Germany1CompletedAstellas PharmaDec 201348
NCT02161224Hepatic Insufficiency · Bulgaria1CompletedAstellas PharmaDec 201316
NCT02052310Anemia · United States, Argentina, Bulgaria and more3CompletedKyntra BioSep 21, 20181,043
NCT02021318Renal Insufficiency, Chronic · Austria, Belarus, Bulgaria and more3CompletedAstellas PharmaMar 23, 2018616
NCT01964196Kidney Failure, Chronic · Japan2CompletedAstellas PharmaJul 6, 2015107
NCT01888445Kidney Failure, Chronic · Japan2CompletedAstellas PharmaSep 15, 2014130
NCT01887600Anemia · Belarus, Belgium, Bulgaria and more3CompletedAstellas PharmaNov 1, 2017594
NCT01750190Anemia · United States, Argentina, Australia and more3CompletedKyntra BioSep 24, 2018922
NCT01630889Renal Insufficiency, Chronic · United States, Puerto Rico2CompletedKyntra BioDec 12, 201915
NCT01599507Anemia · China2CompletedKyntra BioJan 201391
NCT01596855Anemia · China2CompletedKyntra BioJan 201396
NCT01414075Anemia · United States, Hong Kong, Russian Federation and more2CompletedKyntra BioJan 10, 201360
NCT01376063Healthy Adult Subjects1CompletedKyntra BioMay 201020
NCT01244763Renal Insufficiency, Chronic · United States, Puerto Rico2CompletedKyntra BioJun 13, 2012145
NCT01147666Kidney Failure, Chronic · United States2CompletedKyntra BioOct 15, 2012161
NCT01083888Anemia · Japan1CompletedAstellas PharmaJun 7, 201012
NCT00978198Healthy Volunteers · Japan1CompletedAstellas PharmaJun 2010100
NCT00761657Renal Insufficiency, Chronic · United States2CompletedKyntra BioJun 21, 2010117

How it is read

Names in the registry

  • “Roxadustat”, 25 entries
  • “FG-4592”, 9 entries
  • “roxadustat”, 8 entries
  • “ASP1517”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.